Abstract 593P
Background
Multiple MET TKIs are approved or under regulatory review in Asia for treatment of advanced METex14 NSCLC. However, head-to-head studies are lacking. We conducted MAICs of tepotinib vs savolitinib, gumarontinib, or capmatinib in pts in Asia.
Methods
Pt-level data for pts enrolled in Asia in VISION (tepotinib, global trial; data cut-off: Nov 20, 2022) were reweighted to match the baseline characteristics of the overall populations of NCT02897479 (savolitinib, Asian trial) and GLORY (gumarontinib, Asian trial), and pts enrolled in Asia in GEOMETRY mono-1 Cohorts 4/5b (capmatinib, global trial). Pts were stratified by first-/second- or later-line (1L/2L+). Subgroup analyses evaluated VISION pts with METex14 in tissue biopsies (T+). ORR and PFS by IRC, and OS were compared.
Results
Compared with VISION pts overall (n=313), outcomes were similar in pts enrolled in Asia (n=107), or T+ pts in Asia (n=87). Before reweighting, T+ pts enrolled in Asia had an ORR of 67% (95% CI: 53, 80), median (m) PFS of 16.5 months (11.0, ne [not evaluable]), and mOS of 32.7 months (19.1, ne) in 1L (n=46), and ORR of 49% (34, 64), mPFS of 13.8 months (6.9, ne), and mOS of 23.9 months (19.3, ne) in 2L+ (n=41). After reweighting, PFS and OS appeared longer with tepotinib vs savolitinib and gumarontinib in 1L and 2L+ (Table). PFS also seemed longer with tepotinib vs capmatinib in 1L (tepotinib effective sample size [ESS]=5.6; capmatinib, n=3; mPFS: 49.7 [15.9, ne] vs 5.5 months [4.5, ne]) and 2L+ (tepotinib ESS=29.6; capmatinib, n=17; mPFS: 11.1 [5.6, ne] vs 5.0 months [4.1, ne]). Corresponding capmatinib OS data were not available. Improvements with tepotinib vs comparators were also seen in VISION pts overall and pts in Asia, regardless of T+ status. Table: 593P
1L | 2L+ | |||
Tepotinib weighted* | Savolitinib † | Tepotinib weighted* | Savolitinib † | |
n/ESS | 22.0 | 28 | 11.4 | 42 |
ORR, % (95% CI) | 67 (54, 81) | 54 (35, 73) | 39 (24, 54) | 53 (37, 68) |
mPFS, mo (95% CI) | 12.6 (10.8, ne) | 6.9 (5.5, 8.4) | 13.8 (11.0, ne) | 7.0 (4.3, 13.8) |
mOS, mo (95% CI) | 28.5 (22.7, ne) | 10.9 (8.2, 22.5) | 20.8 (17.7, ne) | 17.5 (10.9, 31.5) |
1L | 2L+ | |||
Tepotinib weighted* | Gumarontinib † | Tepotinib weighted* | Gumarontinib † | |
n/ESS | 29.3 | 46 | 14.1 | 38 |
ORR, % (95% CI) | 69 (56, 83) | 71 (56, 83) | 52 (37, 68) | 60 (44, 75) |
mPFS, mo (95% CI) | 22 (8.3, ne) | 11.8 (8.6, ne) | 11.1 (5.5, ne) | 7.6 (4.1, 9.7) |
mOS, mo (95% CI) | nr (13.8, ne) | nr (16.9, ne) | 36.4 (12.3, ne) | 16.2 (11.7, ne) |
nr, not reached.*T+ subgroup of pts enrolled in Asia. †Overall population of an Asian trial in T+ pts.
Conclusions
Based on available evidence (with limited capmatinib subgroup size), the MAICs show no clinically relevant differences in ORR and trends for longer PFS and/or OS with tepotinib vs savolitinib, gumarontinib, or capmatinib in pts in Asia in 1L and 2L+.
Clinical trial identification
CrossRef funder ID: 10.13039/100009945.
Editorial acknowledgement
Medical writing assistance was provided by Bhartendu K Srivastava, PhD, of Syneos Health, London, UK.
Legal entity responsible for the study
Merck Healthcare KGaA, Darmstadt, Germany Merck Healthcare KGaA.
Funding
Merck (CrossRef Funder ID: 10.13039/100009945).
Disclosure
Y. Wu: Financial Interests, Personal, Other, Institute grants and personal fees: AstraZeneca, Roche, Boehringer Ingelheim; Financial Interests, Personal, Speaker, Consultant, Advisor: BMS, MSD, Eili Lilly, Pfizer. T. Douglas, A. Hatswell: Financial Interests, Personal, Full or part-time Employment: Delta Hat Ltd. Y.A. Yao: Financial Interests, Personal, Full or part-time Employment: Merck Serono Co., Ltd., Beijing, China, an affiliate of Merck KGaA. H. Vioix: Financial Interests, Personal, Full or part-time Employment: Merck. All other authors have declared no conflicts of interest.
Resources from the same session
173P - Lenvatinib (L) versus sorafenib (S) second-line therapy in hepatocellular carcinoma (HCC) patients progressed to atezolizumab plus bevacizumab (AB)
Presenter: Mara Persano
Session: Poster Display
Resources:
Abstract
174P - Unlocking the potential of blood-based biomarkers in pancreatic cancer for early detection and therapeutic screening
Presenter: Belinda Lee
Session: Poster Display
Resources:
Abstract
175P - Genomic evolution of peritoneal metastasis in gastric adenocarcinoma
Presenter: Lan Tu
Session: Poster Display
Resources:
Abstract
176P - Identification of novel diagnostic markers for pancreatic neuroendocrine tumors by proteomics with patient blood
Presenter: HEE SEON Kim
Session: Poster Display
Resources:
Abstract
177P - Burden of stomach cancer attributable to smoking in South Asia from 1990-2019, its projection of deaths to 2040: A benchmarking and comparative analysis
Presenter: Pranay Vaghela
Session: Poster Display
Resources:
Abstract
178P - Survival benefit of splenic hilar lymph nodes (no.10) dissection in B4 type gastric carcinoma: An IPTW propensity score analysis of large multi-institutional data
Presenter: Oh Jeong
Session: Poster Display
Resources:
Abstract
179P - The impact of pre-operative nutritional/rehabilitative assessments and support on postoperative outcomes in very elderly gastric cancer patients
Presenter: Yuki Ushimaru
Session: Poster Display
Resources:
Abstract
180P - Appraisal of surgical outcomes and oncological efficiency of intraoperative adverse events in robotic radical gastrectomy for gastric cancer
Presenter: shangguan Zhixin
Session: Poster Display
Resources:
Abstract
181P - TQB2450 (PD-L1 blockade) in combination with anlotinib as a perioperative treatment for patients with hepatocellular carcinoma at high risk of recurrence: Primary results from a prospective, single-arm, phase Ib study
Presenter: Zhen Huang
Session: Poster Display
Resources:
Abstract
182P - Cytoreductive surgery and chemotherapy in metastatic gastric adenocarcinoma: A population-based study
Presenter: Dana Al Zamer
Session: Poster Display
Resources:
Abstract